Reuters: Company News Reuters: Company News
LONDON, May 18 (Reuters) - Generic competition to
cholesterol fighter Crestor and higher costs hit AstraZeneca
in the first quarter, despite good sales of new drugs,
but the group said on Friday it remained on track for a promised
return to sales growth in 2018.